In This Section

Pharmacogenomics to Address Adverse Drug Events
Washington Convention Center, Room 143A/B
3:00 pm – 5:30 pm
Sponsored by the Divisions for Toxicology; Drug Discovery, Development & Regulatory Affairs; and Integrative Systems, Translational & Clinical Pharmacology
Chairs: D.L. Mendrick, NCTR/FDA and P.B. Watkins, Hamner Institue for Health Sci.

Complexity in the analysis of pharmacogenomic data
    Donna L. Mendrick, National Ctr for Toxicology Research/FDA

The application of pharmacogenomics into genetic toxicity and carcinogenicity testing
    Jiri Aubrecht, Pfizer Global Research and Development

Exploring the impact of SNPs of idiosyncratic hepatotoxicity
    Paul B. Watkins, The Hamner Institute for Health Safety Sciences

A risk/benefit view of safety pharmacogenomics
    Issam Zineh, Ctr for Drug Evaluation and Research/FDA

Physiology and Pharmacology of Trace Amine Associated Receptors
Washington Convention Center, Room 143C
3:00 pm – 5:30 pm
Sponsored by the Divisions for Neuropharmacology and Molecular Pharmacology; Behavioral Pharmacology; and Integrative Systems, Translational & Clinical Pharmacology
Chair: R.R. Gainetdinov, Italian Inst. of Technology, Italy and K.A. Neve, VA Med Ctr, Oregon Hlth Sci. Univ.

Trace amine-associated receptor 1 (TAAR1) pharmacology and modulation of brain dopaminergic activity
    Marius C. Hoener, F. Hoffman-La Roche, Ltd.

TAARs and odor-driven behaviors
    Stephen D. Liberles, Harvard Medical School

Structure-activity relationships and species selectivity of TAAR1 ligands
    Anita H. Lewin, RTI International

Trace amine-associated receptor 1 (TAAR1) as an emerging therapeutic target
    Raul R. Gainetdinov, Italian Institute of Technology

Recent Developments in the Understanding of the Biology and Physiology of the JAK Family of Tyrosine Kinases 
Washington Convention Center, Room 140A
3:00 pm – 5:30 pm
Sponsored by the Divisions for Drug Discovery, Development & Regulatory Affairs; Drug Metabolism; Integrative Systems, Translational & Clinical Pharmacology; and Molecular Pharmacology
Chair: M.A. Sills, AD4 Pharma

 Janus kinases: role in cytokine signaling and as therapeutic targets
    John O’Shea

 JAK inhibitors as novel anti-inflammatory agents
    James D. Clark
, Pfizer

 The emerging role of Jak1/Jak2 kinases in solid tumors
    Michael Zinda, AstraZeneca

 JAK1/JAK2 inhibition in myeloproliferative neoplasms and beyond
    Jordan Fridman, Incyte Corporation

Therapeutic Angiogenesis
Washington Convention Center, Room 141
3:00 pm – 5:30 pm
Sponsored by the Divisions for Cardiovascular Pharmacology; Drug Discovery, Development & Regulatory Affairs; and Integrative Systems, Translational & Clinical Pharmacology
Chairs:  S. Sengupta, Harvard-MIT Brigham and Women’s Hosp. and R. Sinha Roy, Harvard-MIT Brigham and Women’s Hosp. 

Adult stem cell therapy for ischemic tissue repair
  A. Mackie, Feinberg Cardiovascular Research Institute, Northwestern Univ  

Stem cells and cardiomyogenesis
  A. Leri, Dana-Farber/Harvard Cancer Center

Engineering biomaterials to control local cellular microenvironments toward therapy development
  J. Burdick, Univ. of Pennsylvania

       Integrating protein engineering and nanotechnology for therapeutic angiogenesis
        R. Sinha Roy, Harvard Med. Sch., Brigham and Women’s Hosp

Therapeutic cardiac angiogenesis and myogenesis: The promises and challenges on a new frontier
  R.C.J. Chiu, McGill Univ. Faculty of Med., Canada


Festschrift Symposium Celebrating More than Three Decades of Mentorship by Dr. Paul Insel
Washington Convention Center, Room 140B
1:00 pm - 5:00 pm

 Session I - Chairs:  K. Meier, Washington State University and J.R. Jasper, Cytokinetics, Inc.

   Kathryn Meier, Washington State Univ

The uninsulated Insel:  A capsule of Paul in Pharmacology at UCSD
  Palmer Taylor, UCSD

Targeting cAMP in chronic lymphocytic leukemia: A pathway-dependent approach
  Fiona Murray, UCSD

ß3-Adrenoceptors as drug targets
  Martin Michel, Univ of Amsterdam

Genetic polymorphisms and prediction of disease progression:  A pediatrician's (critical) view
  Rainer Büscher, University Children's Hospital, Essen


Session II Chairs:  H. Motulsky, GraphPad Software, Inc. and M.C. Michel, University of Amsterdam

Molecular mechanisms of autonomic neuron development
  Marthe Howard, Univ of Toledo

A novel therapeutic strategy for glioma based on clinicopathological analysis
  Hirohishi Nishihara, Hokkaido Univ, Sapporo

New medicines for diseases of the aging population
  R. McKernan, Pfizer Global Research and Development, Sandwich

Paul's Halcyon Days!
  Henry  Bourne, UCSF

Closing remarks:  The PI factor
  Harvey Motulskyk, GraphPad Software, Inc.

Register here for the dinner honoring Paul Insel.


RGS/AGS Proteins in the Visual and Cardiovascular Systems
Washington Convention Center, Room TBD
2:00 pm - 5:00 pm
Sponsored by the Divisions for Molecular Pharmacology and Neuropharmacology
Chairs:  J. R. Hepler, Emory Univ and V. Zachariou, University of Crete, Greece

Note:  This session is part of a colloquium on RGS/AGS Proteins in Physiology and Disease which continues Wednesday evening and Thursday morning.  While this session on the visual and cardiovascular systems is open to any EB registrant, attendance at the poster sessions, dinner and remainder of the colloquium Wednesday evening and Thursday requires separate registration.

R7 RGS regulation of Class A and Class C GPCR Pathways
T. Wensel,
Baylor College of Medicine

Visual system:  AGS/PcP2/Go signaling in retina
  N. Vardi, Univ of Pennsylvania

Inflammation and cardiovascular disease:  RGS in bronchial smooth muscle/asthma
  K. Druey, NIAID/NIH

Inflammation and cardiovascular disease: RGS modulation of myocyte stress responses in heart disease
 David Kass, Johns Hopkins Univ

Inflammation and cardiovascular disease: RGS proteins in cardiovascular function
  Scott Heximer, Univ of Toronto

 For the remainder of the RGS/AGS Proteins in Physiology and Disease Program, click HERE





Last Updated: July 28, 2017

Job Postings